Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial
{{output}}
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evalu... ...
